Canada is hosting discussions on legal access to psychedelic-assisted therapies, especially after Alberta passed regulatory measures for this type of health service. 

So, does this mean that those who could benefit from these treatments will soon be able to lawfully request them? 

Health Canada places psilocybin and psilocin under Schedule III of the Controlled Drug and Substances Act (CDSA), which means production, sale and possession are illegal unless authorized via a Special Access Program (SAP)’s license, an individual exemption or clinical trials.

The state’s psilocybin law, which implies that constitutional access to the psychedelic must be done through a doctor, was recently questioned in a lawsuit on behalf of seven terminally-ill patients. Nonprofit Therapsil also legally challenged patients’ inability to obtain an exemption.  

As reporter Dave Hodes recalls, Therapsil’s psilocybin access challenge takes two major cannabis cases –R v. Parker in 2000 and R. v. Smith in 2015- as precedents where the court actually recognized and consequently ruled on the fact the prohibition of cannabis by the CDSA is a mistake.

After both rulings, Canada finally amended the CDSA to allow for the medical use of cannabis without any further bureaucratic approval.

Now, what the Canadian government ultimately decides is believed to be directly connected to what might happen with the psilocybin legalization in the US and psilocybin access as medicine as well as for general well-being purposes.

Reactions Following Alberta’s New Policy

The provincial government of Alberta has decided to regulate psychedelics psilocybin, psilocin, MDMA, LSD, mescaline, DMT, 5-MeO-DMT and ketamine as treatments for psychiatric disorders.

Alberta’s associate minister of health and addictions and …

Full story available on